s6y

In Vitro & In Vivo Diagnostic Substances

21 listed companies the SEC classes under this industry (code 2835), in order of revenue.

20 of them have annual figures on record. The 20 reporting in US dollars had revenue of $10.5B between them in their latest fiscal years.

Company Fiscal year to
Idexx Laboratories Inc Dec 2025 $4.30B$1.06B$3.35B
QuidelOrtho Corp Dec 2025 $2.73B−$1.13B$5.77B
Lantheus Holdings, Inc. Dec 2025 $1.54B$233.6M$2.23B
Neogen Corp May 2026 $870.4M−$7.90M$3.35B
Myriad Genetics Inc Dec 2025 $824.5M−$365.9M$706.6M
Intellia Therapeutics, Inc. Dec 2025 $67.7M−$412.7M$842.1M
Trinity Biotech plc Dec 2024 $61.6M−$31.8M$103.3M
Alpha Teknova, Inc. Dec 2025 $40.5M−$17.3M$103.6M
Immucell Corp Dec 2025 $27.6M−$1.04M$42.5M
Aspira Women's Health Inc. Dec 2025 $9.22M−$12.8M$5.46M
Anbio Biotechnology Dec 2025 $8.65M$6.40M$30.2M
Biomerica Inc May 2026 $4.45M−$3.77M$6.76M
Insight Molecular Diagnostics Inc. Dec 2025 $4.05M−$50.2M$25.8M
Volitionrx Ltd Dec 2025 $1.73M−$23.4M$6.90M
Celldex Therapeutics, Inc. Dec 2025 $1.54M−$258.8M$583.0M
Cardio Diagnostics Holdings, Inc. Dec 2025 $14.8K−$6.50M$7.77M
Achieve Life Sciences, Inc. Dec 2025 –−$54.6M$41.8M
Q/C Technologies, Inc. Dec 2025 –−$11.6M$41.2M
Nymox Pharmaceutical Corp Dec 2024 –−$4.49M$654.0K
Virax Biolabs Group Ltd Mar 2025 –−$6.06M$6.43M
Asep Medical Holdings Inc.

Each company's latest fiscal year, as its annual report to the SEC gave the figures; the year links to that report. Amounts in other currencies are not converted, and sort after those in dollars.